Japanese drugmaker Sosei (TYO: 4565) has appointed a chief operating officer, Toshihiro Maeda, a new role at the company.
Mr Maeda was formerly a business unit lead at Bristol Myers Squibb (NYSE: BMY).
At Bristol Myers, he played an important role in the post-merger integration of Celgene’s businesses and commercial strategies for the combined group in Japan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze